Melatonin inhibits LDL receptor activity and cholesterol synthesis in freshly isolated human mononuclear leukocytes.
There is some indirect evidence that the pineal hormone melatonin can suppress plasma levels of cholesterol in hypercholesterolemic rats. We have examined the effects of the hormone on cellular cholesterol metabolism in freshly isolated human mononuclear leukocytes. Incubation of cells for up to 20 h in a lipid-free medium resulted in an increase in the rate of cholesterol synthesis from [14C]acetate and the high affinity accumulation and degradation of [125I]labeled low density lipoprotein (LDL). Addition of melatonin in increasing concentrations to the incubation medium at zero time inhibited cholesterol synthesis and the specific accumulation and degradation of [125I]labeled LDL; at a concentration of 100 microM, the inhibitions were 38%, 42%, and 48%, respectively. Similar results were obtained using [14C]mevalonate as precursor. Fatty acid synthesis was not altered under these conditions. In contrast to cholesterol, the synthesis of the first cyclic compound lanosterol was not affected by the pineal hormone. These results implicate that melatonin inhibits this pathway between lanosterol and cholesterol. The action of melatonin on LDL receptor activity appeared to be mediated by a decrease in the number of LDL receptors and not by a change in binding affinity. Pharmacological characterization of the potential melatonin receptor site using several analogs like tryptamine, 5-hydroxytryptamine,N-acetyl-5-hydroxytryptamine, 5-methoxytryptamine, and 6-chloromelatonin indicated that the 5-methoxy group is indispensible for the hormone action on cholesterol synthesis. The data provide evidence that melatonin can modulate cholesterol metabolism in human cells.
Müller-Wieland
D
D
Klinik II und Poliklinik für Innere Medizin, Universität zu Köln, Germany.
Behnke
B
B
Koopmann
K
K
Krone
W
W
D008735:5-Methoxytryptamine / Q000494:pharmacology; D000085:Acetates / Q000378:metabolism; D002250:Carbon Radioisotopes; D002784:Cholesterol / Q000096:biosynthesis* / Q000097:blood; D002852:Chromatography, Ion Exchange; D004305:Dose-Response Relationship, Drug; D006801:Humans; D066298:In Vitro Techniques; D007457:Iodine Radioisotopes; D007700:Kinetics; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000097:blood / Q000302:isolation & purification; D008550:Melatonin / Q000031:analogs & derivatives / Q000494:pharmacology*; D008798:Mevalonic Acid / Q000378:metabolism; D011973:Receptors, LDL / Q000037:antagonists & inhibitors / Q000378:metabolism*; D012701:Serotonin / Q000031:analogs & derivatives / Q000494:pharmacology; D014363:Tryptamines / Q000494:pharmacology
D000085:Acetates; D002250:Carbon Radioisotopes; D007457:Iodine Radioisotopes; D008077:Lipoproteins, LDL; D011973:Receptors, LDL; D014363:Tryptamines; D012701:Serotonin; D008735:5-Methoxytryptamine; C030820:tryptamine; C024100:6-chloromelatonin; D002784:Cholesterol; D008550:Melatonin; C006389:N-acetylserotonin; D008798:Mevalonic Acid